CL2011000109A1 - Formulacion farmaceutica que comprende 30-70% de etilester del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo anionico y un polimero enterico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso. - Google Patents

Formulacion farmaceutica que comprende 30-70% de etilester del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo anionico y un polimero enterico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso.

Info

Publication number
CL2011000109A1
CL2011000109A1 CL2011000109A CL2011000109A CL2011000109A1 CL 2011000109 A1 CL2011000109 A1 CL 2011000109A1 CL 2011000109 A CL2011000109 A CL 2011000109A CL 2011000109 A CL2011000109 A CL 2011000109A CL 2011000109 A1 CL2011000109 A1 CL 2011000109A1
Authority
CL
Chile
Prior art keywords
hyperexitability
retigabine
fluorobenzylamino
disorder
treat
Prior art date
Application number
CL2011000109A
Other languages
English (en)
Spanish (es)
Inventor
Biljana Nadjsombati
Original Assignee
Valeant Pharmaceuticals Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000109(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valeant Pharmaceuticals Int filed Critical Valeant Pharmaceuticals Int
Publication of CL2011000109A1 publication Critical patent/CL2011000109A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2011000109A 2008-07-18 2011-01-18 Formulacion farmaceutica que comprende 30-70% de etilester del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo anionico y un polimero enterico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso. CL2011000109A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8216208P 2008-07-18 2008-07-18

Publications (1)

Publication Number Publication Date
CL2011000109A1 true CL2011000109A1 (es) 2011-11-25

Family

ID=41550741

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000109A CL2011000109A1 (es) 2008-07-18 2011-01-18 Formulacion farmaceutica que comprende 30-70% de etilester del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo anionico y un polimero enterico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso.

Country Status (16)

Country Link
US (1) US20100120906A1 (https=)
EP (1) EP2318001A4 (https=)
JP (1) JP2011528666A (https=)
KR (1) KR20110052641A (https=)
CN (1) CN102170879B (https=)
AU (1) AU2009270768A1 (https=)
BR (1) BRPI0916000A2 (https=)
CA (1) CA2731008A1 (https=)
CL (1) CL2011000109A1 (https=)
CO (1) CO6351716A2 (https=)
EA (1) EA201170230A1 (https=)
IL (1) IL210683A0 (https=)
MX (1) MX2011000636A (https=)
NZ (1) NZ590885A (https=)
WO (1) WO2010009433A1 (https=)
ZA (1) ZA201102518B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009013613A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
US10786464B2 (en) * 2009-11-03 2020-09-29 Lupin Limited Modified release formulation of lacosamide
EP2525660A4 (en) * 2010-01-20 2013-08-07 Valeant Pharmaceuticals Int FORMULATION WITH MODIFIED RELEASE AND USE METHOD
EP2525788A2 (en) 2010-01-20 2012-11-28 Glaxo Group Limited Novel retigabine composition
SG191309A1 (en) 2011-01-18 2013-07-31 Glaxo Group Ltd Process for the preparation of retigabine
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
MA43532A (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals Inc Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
CA3162907A1 (en) * 2019-12-02 2021-06-10 Xenon Pharmaceuticals Inc. Pediatric immediate-release formulation of the potassium channel opener ezogabine
CN117321031A (zh) * 2021-03-19 2023-12-29 艾可斯外扎根股份有限公司 Kv7通道开放剂的前药

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
JP2000086509A (ja) * 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
NZ527771A (en) * 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
WO2001066081A2 (de) * 2000-03-08 2001-09-13 Awd.Pharma Gmbh & Co.Kg Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
WO2002043704A1 (fr) * 2000-12-01 2002-06-06 Kyowa Hakko Kogyo Co., Ltd. Composition a solubilite ou absorbabilite orale amelioree
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2003260336C1 (en) * 2002-07-29 2008-05-29 Glaxo Group Limited Sustained release formulations comprising lamotrigine
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
JP2004131393A (ja) * 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
JP2007506775A (ja) * 2003-09-26 2007-03-22 アルザ・コーポレーシヨン 漸増する放出速度を表す制御放出製剤
GB0324574D0 (en) * 2003-10-21 2003-11-26 Glaxo Group Ltd Novel compositions
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
US20080020041A1 (en) * 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20100285123A1 (en) * 2005-06-20 2010-11-11 Rudresha Korlakunte Virupakshalah Prasad Controlled Release Dosage Formulation of Duloxetine
EP2404604B1 (en) * 2006-01-05 2019-02-06 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US8558470B2 (en) * 2006-01-20 2013-10-15 Point Somee Limited Liability Company Adaptive current regulation for solid state lighting
USD601689S1 (en) * 2006-05-12 2009-10-06 Glaxo Group Limited Pharmaceutical tablet
CA2670966A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators

Also Published As

Publication number Publication date
EP2318001A4 (en) 2013-02-20
CN102170879B (zh) 2014-03-05
KR20110052641A (ko) 2011-05-18
BRPI0916000A2 (pt) 2019-09-24
EP2318001A1 (en) 2011-05-11
IL210683A0 (en) 2011-03-31
AU2009270768A1 (en) 2010-01-21
US20100120906A1 (en) 2010-05-13
ZA201102518B (en) 2012-06-27
EA201170230A1 (ru) 2011-08-30
JP2011528666A (ja) 2011-11-24
MX2011000636A (es) 2011-08-03
WO2010009433A1 (en) 2010-01-21
CA2731008A1 (en) 2010-01-21
CN102170879A (zh) 2011-08-31
NZ590885A (en) 2013-01-25
CO6351716A2 (es) 2011-12-20

Similar Documents

Publication Publication Date Title
CL2011000109A1 (es) Formulacion farmaceutica que comprende 30-70% de etilester del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo anionico y un polimero enterico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso.
ES2653207T3 (es) Preparación líquida para protección biológica de plantas, procedimiento para su producción y uso de la misma
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CL2007003491A1 (es) Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica.
CL2008002998A1 (es) Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
CL2008000063A1 (es) Microcapsula que comprende una aglomeracion de microcapsulas primarias y una sustancia de carga; proceso de preparacion; y su uso para entregar una sustancia de carga a un sujeto.
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.
WO2016014975A3 (en) Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
CL2007001972A1 (es) Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos.
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
CL2009000882A1 (es) Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer.
CL2007000361A1 (es) Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
CL2011002460A1 (es) Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple.
CL2011002964A1 (es) Composicion para controlar enfermedades de plantas que comprende acido 4-oxo-4-[(2-feniletilamino]-butirico y un inhibidor ajeno a quinona; agente de tratamiento de semillas; y uso.
EA201200728A1 (ru) Новые сокристаллы агомелатина, способ их получения и фармацевтические композиции, которые их содержат
BR112022022431A2 (pt) Composição amaciante sólida de tecido, tablete amaciante de tecido, método de produção de um tablete amaciante de tecido, método de amaciamento de roupas e uso de uma composição amaciante sólida de tecido
CO6470857A2 (es) Lipopolisacárido de ochrobactrum intermedium y su uso como inmunoestimulante en mamiferos
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
ECSP15022442A (es) Producto de comicronización que comprende acetato de ulipristal
BR112016022247A2 (pt) Síntese eficaz de aminas e amidas a partir de álcoois e aldeídos com o uso de catálise em cascata
CL2008001810A1 (es) Compuestos derivados de espiroindolinas, moduladores de receptores de quimiocinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar aterosclerosis, dolor inflamatorio, influenza, sindrome metabolico, entre otras enfermedades.
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.